Eli Lilly And Company Share Price (NYSE: LLY)

$727

▲

31.67

(4.55%)

Live

Last updated on August 27, 2025 at 1:29 AM IST

$₹

Check the interactive Eli Lilly And Company Stock chart to analyse performance

Eli Lilly And Company stock performance

as on August 27, 2025 at 1:29 AM IST

Today's Low:$713.87
Today's High:$728.14
$727.00
1.81%
Downside
Day's Volatility :1.96%
Upside
0.16%
52 Weeks Low:$623.78
52 Weeks High:$972.48
$727.00
14.2%
Downside
52 Weeks Volatility :35.86%
Upside
25.24%

Eli Lilly And Company Stock Returns

Period	Eli Lilly And Company	Sector (Health Care)	S&P500
3 Months	-4.11%	4.5%	11.0%
6 Months	-22.89%	-7.9%	8.1%
1 Year	-26.84%	-12.3%	14.6%
3 Years	124.22%	7.0%	58.7%

Eli Lilly And Company Key Stats

Check Eli Lilly And Company key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$695.33
Open	$710.01
Today's High	$736.02
Today's Low	$713.87
Market Capitalization	$623.3B
Today's Volume	$2.9M
52 Week High	$972.48
52 Week Low	$623.78
Revenue TTM	$53.3B
EBITDA	$24.8B
Earnings Per Share (EPS)	$15.3
PE Ratio	45.45
Dividend Yield	0.79%
Profit Margin	25.91%
Quarterly Earnings Growth YOY	0.92%
Return On Equity TTM	86.29%

Stock Returns calculator for Eli Lilly And Company Stock including INR - Dollar returns

The Eli Lilly And Company stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Eli Lilly And Company investment value today

Current value as on today

₹81,011

Returns

₹18,989

(-18.99%)

Returns from Eli Lilly And Company Stock

₹23,516 (-23.52%)

Dollar Returns*

₹4,527 (+4.53%)

Indian investors sentiment towards Eli Lilly And Company Stock

127.43%

Period: Jul 26, 2025 to Aug 25, 2025. Change in 30 Days versus previous period

Investment in Eli Lilly And Company Shares from India has grown by 127.43% over the past 30 days, indicating increased transactional activity.

116%

Period: Jul 26, 2025 to Aug 25, 2025. Change in 30 Days versus previous period

Search interest for Eli Lilly And Company Stock from India on INDmoney has increased by 116% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Eli Lilly And Company Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	6358	880.27	1.08%
Aditya Birla Sun Life International Equity Fund Direct Plan Growth	400	-	1.13%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	1272	0.00	4.98%
Axis Innovation Fund Direct Growth	637	17.84	0.35%

Global Institutional Holdings in Eli Lilly And Company

Name
Holdings %
Name
Holdings %
PNC Financial Services Group Inc
11.30%
Lilly Endowment Inc
10.71%
Vanguard Group Inc
8.97%
BlackRock Inc
7.32%
State Street Corp
3.84%
FMR Inc
3.17%

Analyst Recommendation on Eli Lilly And Company Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 32 Wall street analysts offering stock ratings for Eli Lilly And Company(by analysts ranked 0 to 5 stars)

Eli Lilly And Company Share Price Target

What analysts predicted

Upside of 22.09%

Target:

$887.60

Current:

$727.00

Eli Lilly And Company share price target is $887.60, a slight Upside of 22.09% compared to current price of $727.00 as per analysts' prediction.

Eli Lilly And Company Stock Insights

Price Movement
In the last 7 days, LLY stock has moved down by -1.1%
Increasing Revenue
Eli Lilly And Company has shown strong revenue growth over the last two quarters, increasing from $12.72 billion to $15.55 billion. This represents an average increase of 18.2% in revenue per quarter.
Increasing Net Profit
Eli Lilly And Company has shown strong profit growth over the last two quarters. Their net profit increased from $2.75 billion to $5.66 billion, representing an average increase of 51.3% per quarter.
LLY vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 8.4% return, outperforming this stock by 35.2%
Price to Sales
Eli Lilly And Company has a Price-to-Sales Ratio of 11.7, which means investors are willing to pay $11.70 for every $1 of sales the company generates. In comparison, Johnson & Johnson has a Price-to-Sales Ratio of 4.7, indicating that investors pay significantly less, at $4.70 for every $1 of sales. This suggests that investors have higher expectations for Eli Lilly's future growth compared to Johnson & Johnson.

Eli Lilly And Company Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$22.3B	↑ 3.84%
Net Income	$8.3B	↑ 157.38%
Net Profit Margin	37.27%	↑ 22.23%

	FY20	Y/Y Change
Revenue	$24.5B	↑ 9.95%
Net Income	$6.2B	↓ 25.54%
Net Profit Margin	25.24%	↓ 12.03%

	FY21	Y/Y Change
Revenue	$28.3B	↑ 15.4%
Net Income	$5.6B	↓ 9.88%
Net Profit Margin	19.71%	↓ 5.53%

	FY22	Y/Y Change
Revenue	$28.5B	↑ 0.79%
Net Income	$6.2B	↑ 11.88%
Net Profit Margin	21.88%	↑ 2.17%

	FY23	Y/Y Change
Revenue	$34.1B	↑ 19.56%
Net Income	$5.2B	↓ 16.08%
Net Profit Margin	15.36%	↓ 6.52%

	FY24	Y/Y Change
Revenue	$45.0B	↑ 32.0%
Net Income	$10.6B	↑ 102.08%
Net Profit Margin	23.51%	↑ 8.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$8.8B	↓ 6.26%
Net Income	$2.2B	↑ 2.43%
Net Profit Margin	25.58%	↑ 2.17%

	Q2 FY24	Q/Q Change
Revenue	$11.3B	↑ 28.91%
Net Income	$3.0B	↑ 32.28%
Net Profit Margin	26.25%	↑ 0.67%

	Q3 FY24	Q/Q Change
Revenue	$11.4B	↑ 1.21%
Net Income	$970.3M	↓ 67.3%
Net Profit Margin	8.48%	↓ 17.77%

	Q4 FY24	Q/Q Change
Revenue	$13.5B	↑ 18.3%
Net Income	$4.4B	↑ 354.48%
Net Profit Margin	32.59%	↑ 24.11%

	Q1 FY25	Q/Q Change
Revenue	$12.7B	↓ 5.94%
Net Income	$2.8B	↓ 37.43%
Net Profit Margin	21.68%	↓ 10.91%

	Q2 FY25	Q/Q Change
Revenue	$15.6B	↑ 22.23%
Net Income	$5.7B	↑ 105.14%
Net Profit Margin	36.38%	↑ 14.7%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$17.6B	↑ 4.68%

	FY20	Y/Y Change
Profit	$19.1B	↑ 8.29%

	FY21	Y/Y Change
Profit	$21.0B	↑ 10.23%

	FY22	Y/Y Change
Profit	$21.9B	↑ 4.31%

	FY23	Y/Y Change
Profit	$27.0B	↑ 23.41%

	FY24	Y/Y Change
Profit	$36.6B	↑ 35.44%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$7.1B	↓ 6.22%

	Q2 FY24	Q/Q Change
Profit	$9.1B	↑ 28.73%

	Q3 FY24	Q/Q Change
Profit	$9.3B	↑ 1.49%

	Q4 FY24	Q/Q Change
Profit	$11.1B	↑ 20.08%

	Q1 FY25	Q/Q Change
Profit	$10.5B	↓ 5.61%

	Q2 FY25	Q/Q Change
Profit	$13.1B	↑ 24.81%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$4.8B	↓ 12.45%
Investing Cash Flow	$-8.1B	↓ 524.08%
Financing Cash Flow	$-2.3B	↓ 60.63%

	FY20	Y/Y Change
Operating Cash Flow	$6.5B	↑ 34.38%
Investing Cash Flow	$-2.3B	↓ 72.05%
Financing Cash Flow	$-3.1B	↑ 34.96%

	FY21	Y/Y Change
Operating Cash Flow	$7.3B	↑ 11.71%
Investing Cash Flow	$-2.9B	↑ 26.94%
Financing Cash Flow	$-4.1B	↑ 31.69%

	FY22	Y/Y Change
Operating Cash Flow	$7.1B	↓ 2.43%
Investing Cash Flow	$-3.8B	↑ 31.23%
Financing Cash Flow	$-5.4B	↑ 30.87%

	FY23	Y/Y Change
Operating Cash Flow	$4.2B	↓ 40.15%
Investing Cash Flow	$-7.2B	↑ 90.08%
Financing Cash Flow	$3.5B	↓ 164.65%

	FY24	Y/Y Change
Operating Cash Flow	$8.8B	↑ 107.96%
Investing Cash Flow	$-9.3B	↑ 30.04%
Financing Cash Flow	$1.2B	↓ 64.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.2B	↓ 473.84%
Investing Cash Flow	$-1.2B	↓ 59.73%
Financing Cash Flow	$-311.3M	↓ 108.78%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.5B	↑ 25.75%
Investing Cash Flow	$-2.2B	↑ 86.71%
Financing Cash Flow	$1.6B	↓ 599.68%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.7B	↑ 153.16%
Investing Cash Flow	$-4.0B	↑ 82.14%
Financing Cash Flow	$211.3M	↓ 86.42%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.5B	↓ 33.35%
Investing Cash Flow	$-1.9B	↓ 52.04%
Financing Cash Flow	$-225.4M	↓ 206.67%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.7B	↓ 32.67%
Investing Cash Flow	$-3.4B	↑ 74.55%
Financing Cash Flow	$1.4B	↓ 712.11%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$3.1B	↑ 85.33%
Investing Cash Flow	$-1.8B	↓ 45.26%
Financing Cash Flow	$-1.2B	↓ 190.23%

Eli Lilly And Company Technicals Summary

Sell

Neutral

Buy

Eli Lilly And Company is currently in a neutral trading position according to technical analysis indicators.

Eli Lilly And Company Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Eli Lilly And Company	-13.94%	-22.89%	-26.84%	124.22%	366.82%
Johnson & Johnson	7.34%	7.42%	8.39%	9.46%	16.63%
Pfizer Inc.	3.37%	-6.02%	-13.11%	-45.64%	-33.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Eli Lilly And Company	45.45	45.45	1.03	22.86	0.86	0.17	0.01	20.38
Johnson & Johnson	19.1	19.1	1.09	10.85	0.3	0.08	0.03	32.6
Pfizer Inc.	13.69	13.69	0.87	3.07	0.12	0.05	0.07	15.6

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Eli Lilly And Company	Buy	$623.3B	366.82%	45.45	25.91%
Johnson & Johnson	Buy	$429.7B	16.63%	19.1	25.0%
Pfizer Inc.	Hold	$147.1B	-33.62%	13.69	16.84%

Eli Lilly And Company Dividend announcements

Eli Lilly And Company Dividends September, 2025
In the quarter ending September,2025. Eli Lilly And Company has declared dividend of $1.50

About Eli Lilly And Company

Lilly (Eli) & Co. is an American-based multinational pharma company with offices in 18 countries. Its headquarters are situated in Indianapolis, Indiana, and it sells drugs in over 125 countries. Colonel Eli Lilly was a pharmaceutical chemist and American Civil War veteran who founded this company in 1876. It is traded as LLY in the New York Stock Exchange (NYSE). Lilly employs over 33,000 people and generated a revenue of over 22 billion USD as of 2019. The company is committed to researching and developing high-quality drugs for humankind's welfare by remaining true to its work. In 1876, this company produced the medicinal drug called quinine used in the treatment of Malaria. Among its many commendable innovations were gelatin-coating for the capsules & pills and sugar-coated pills that make them easier to swallow. It also developed various drugs for treating syphilis, rheumatism, eczema, and psoriasis in the early 1880s. A scientific journal asserted that the Lilly operation was the largest capsule factory in the world in 1917. In 1923, Lilly mass-produced the Insulin under the name “Iletin” used to treat diabetes in the US. Moreover, it also became the company to mass-produce Penicillin in the 1940s and started producing the Polio vaccine in the early 1950s. It acquired CoLucid in 20017 for 960mn USD and Armo Biosciences for 1.6bn USD in 2018. Also, it purchased the Aurora Kinase A, an inhibitor developer, for 575mn USD. It acquired multiple companies for developing and researching breakthroughs. The company aims to bring life-changing research to the community while performing voluntary & philanthropist operations worldwide. Currently Eli Lilly And Company has a market cap of $893.59 Billion. It has a P.E ratio of 121.71. The shares of Eli Lilly And Company are trading at $695.42. .

Organization	Eli Lilly And Company
Employees	47000
CEO	Mr. David A. Ricks
Industry	Health Technology

Key Management of Eli Lilly And Company

Name	Title
Mr. David A. Ricks	Chairman, CEO & President
Mr. Lucas E. Montarce	Executive VP & CFO
Dr. Daniel M. Skovronsky M.D., Ph.D.	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Ms. Anat Hakim J.D.	Executive VP, General Counsel & Secretary
Mr. Jacob S. Van Naarden	Executive VP & President of Lilly Oncology
Mr. Gordon Brooks	Group VP, Controller & Corporate Strategy
Mr. Donald A. Zakrowski	Senior VP of Finance & Chief Accounting Officer
Mr. Diogo Rau	EVP & Chief Information and Digital Officer
Mr. Eric Dozier	Executive VP & Chief People Officer
Mr. Jeffrey N. Simmons	Senior VP & President of Elanco Animal Health

Important FAQs about investing in LLY Stock from India :

What is Eli Lilly And Company share price today?

Eli Lilly And Company share price today is $727.00 as on August 27, 2025 at 1:29 AM IST. Eli Lilly And Company share today touched a day high of $728.14 and a low of $713.87.

What is the 52 week high and 52 week low for Eli Lilly And Company share?

Eli Lilly And Company share touched a 52 week high of $972.48 and a 52 week low of $623.78. Eli Lilly And Company stock price today i.e. August 27, 2025 at 1:29 AM IST is trending at $727.00, lower by 25.24% versus the 52 week high.

How to invest in Eli Lilly And Company Stock (LLY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Eli Lilly And Company on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eli Lilly And Company Shares that will get you 0.0021 shares as per Eli Lilly And Company share price of $727.00 per share as on August 27, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Eli Lilly And Company Stock (LLY) from India?

Indian investors can start investing in Eli Lilly And Company (LLY) shares with as little as ₹87.6525 or $1 (as of August 26, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.53 in Eli Lilly And Company stock (as per the Rupee-Dollar exchange rate as on August 26, 2025). Based on Eli Lilly And Company share’s latest price of $727.00 as on August 27, 2025 at 1:29 AM IST, you will get 0.0138 shares of Eli Lilly And Company. Learn more about fractional shares .

What are the returns that Eli Lilly And Company has given to Indian investors in the last 5 years?

Eli Lilly And Company stock has given 366.82% share price returns and 18.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?